(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 November 2006 (16.11.2006)

PCT

(10) International Publication Number
WO 2006/120252 A3

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 31/14* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/EP2006/062290

(22) International Filing Date: 12 May 2006 (12.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/680,405	12 May 2005 (12.05.2005)	US
05106214.9	7 July 2005 (07.07.2005)	EP
06075855.4	6 April 2006 (06.04.2006)	EP

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Eastgate Village, Eastgate, Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SIMMEN, Kenneth Alan** [GB/BE]; Boterbloemenlaan 35, B-3080 Tervuren (BE). **SURLERAUX, Dominique Louis Nestor Ghislain** [BE/BE]; Rue de la Scaillée, 13, B-1440 Braine-le-Château (BE). **LIN, Tse-I** [CN/BE]; Hoogstraat 31, B-2800 Mechelen (BE). **LENZ, Oliver** [DE/BE]; Kanadastraat 14, B-2860 Sint-Katelijne-Waver (BE). **RABOISSON, Pierre Jean-Marie Bernard** [FR/BE]; Sint Pancratiuslaa 26, B-1933 Sterrebeek (BE).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11b 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
22 February 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF

(57) Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines as inhibitors of 10 HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to pyrido- [2,3-d]pyrimidines co mpounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceut ical compositions co mprising them, and combinations of said compounds 15 with other anti-HCV agents.

WO 2006/120252 A3